New Fibromyalgia Treatments Have Arrived

For years, people with fibromyalgia have heard the same message: options are limited, improvement is unpredictable, and care mostly means managing symptoms. That’s beginning to change. Neuromodulation, photobiomodulation, and prescription digital therapeutics now represent a genuine shift in how chronic pain is understood and treated. These are not just new alternatives to medication. There are new fibromyalgia treatments available to patients. 

But a treatment that exists is not the same as a treatment you can get. Even after FDA authorization, a technology can reach clinicians and still sit out of reach, because regulatory approval and insurance coverage are two separate hurdles. For people with fibromyalgia, innovation without access delivers very little.

Three recent examples show how far the field has moved beyond medication, exercise advice, and symptom management:

• Quell Fibromyalgia (NeuroMetrix) is a wearable neuromodulation device that received FDA De Novo authorization in 2022 as an aid for reducing fibromyalgia symptoms in adults with high pain sensitivity.
• FibroLux (Multi Radiance Medical) is an FDA-cleared therapeutic laser using photobiomodulation for the temporary relief of pain associated with fibromyalgia.
• Stanza (Swing Therapeutics) is a prescription digital therapeutic, FDA-authorized to treat fibromyalgia symptoms, delivering Acceptance and Commitment Therapy through a smartphone.

Three very different technologies, and definitive proof that fibromyalgia care is finally expanding. The shift isn’t limited to devices. In 2025, Tonmya became the first new fibromyalgia medication in over 15 years, and as a newly launched branded drug, it faces the same coverage and prior authorization questions.

FDA Authorization Doesn’t Mean Insurance Coverage.

FDA authorization does not obligate any insurer to pay. Health plans run their own evaluations, weighing clinical evidence, durability of benefit, medical necessity, coding, comparative effectiveness, and cost before deciding whether to cover a treatment.

That scrutiny is appropriate. Not every new technology earns automatic reimbursement simply for reaching the market. But patients should not be stranded between a system that lets a treatment be marketed and another that offers no realistic way to obtain it. That gap is where fibromyalgia patients actually live, and they know it well.

A physician may be willing to prescribe. A patient may meet every clinical criterion and have already failed multiple prior treatments. Then comes the question that decides everything: who pays for it?

When insurance says no, the patient pays. For some families, a few hundred dollars is a strain; for others, impossible. Treatment decisions stop being about clinical fit and start being about disposable income. For a condition already tied to work limitations, disability, and years of trial and error, that’s no minor distinction. It is an access problem.

Coverage Is Possible – Stanza Shows the Path.

There’s reason for optimism. Stanza has secured commercial insurance coverage in parts of the market. Highmark now reimburses it for members across Pennsylvania, West Virginia, Delaware, and New York; though that footprint is still early and narrow.

This doesn’t mean Stanza is right for every patient, or that other technologies can follow the identical path. It matters because it proves a fibromyalgia-specific treatment can move from FDA authorization into a coverage pathway. And it raises more productive questions: What evidence let one therapy cross that threshold? Stanza’s pivotal trial results were published in The Lancet in 2024. What, specifically, are payers still asking of the others? Longer-term outcomes? Comparative studies? Functional improvement? Reduced healthcare utilization?

Just as important: is there a clear way for manufacturers, researchers, clinicians, and patient organizations to find those answers? Coverage policies should be transparent. If a treatment misses an evidentiary threshold, the field should know what’s missing and what studies would close the gap. When new evidence arrives, medical policy should have a real pathway for reconsideration. That is how an evidence-based system is supposed to work.

Are Old Coverage Categories Being Applied to New Technology?

Emerging devices often get routed into reimbursement frameworks built for older tools. A newer neuromodulation device may be judged against policies written for conventional electrical stimulation; a photobiomodulation therapy may be evaluated through a lens shaped by decades-old laser literature.

That doesn’t automatically make those policies wrong. It’s worth asking whether insurers are assessing current technologies in the right patient populations, using the most relevant evidence. Medicine changes, and coverage should change with it. That’s not about lowering standards. It’s about applying them to the right technology, indication, and evidence.

What Nurses See After the Prescription.

One part of this conversation gets too little attention: what actually happens after a treatment is prescribed. Nurses live in that space. We see the insurance denial, the medication stopped for side effects, the patient who can’t afford the next step. We see whether symptoms improve, whether function returns, whether sleep gets better, and whether a treatment is even being used.

For fibromyalgia, that’s an opening to document outcomes far more systematically. Validated tools like the Revised Fibromyalgia Impact Questionnaire can be paired with measures of pain interference, sleep, physical function, patient-reported improvement, and adherence. Instead of noting that a patient “feels better,” we can define what better means: Can they walk farther? Return to work? Sleep through the night? Tolerate activity that used to be impossible? Those are the outcomes patients care about most and the ones coverage decisions should weigh most heavily.

What Patient Organizations Can Do.

Patient organizations should never become marketing arms for manufacturers. Our job isn’t to promote every new device or argue that everything deserves reimbursement. It’s to make sure patients are represented when access decisions get made.

In practice, that means documenting insurance barriers, gathering de-identified denial trends, teaching patients how to appeal, encouraging standardized outcome tracking, and bringing researchers, clinicians, manufacturers, and payers into the same room. It also means asking why an evidence-supported treatment stays out of reach long after approval. The goal isn’t automatic coverage or automatic rejection. It’s a transparent path from evidence to appropriate access.

Fibromyalgia Care is Changing. Access Has to Change With it.

For decades, the frustration of fibromyalgia was how few real options patients were offered. Serious innovation deserves a real welcome. Some technologies will prove more useful than others. Some will help only certain subgroups, some will need stronger research, and some may never justify broad coverage. That’s science.

But there’s a difference between requiring evidence and letting reimbursement become an insurmountable wall. Patients deserve to know what evidence is required. Researchers deserve to know what questions remain. Clinicians deserve clearer paths to request appropriate treatment. And insurers should have real mechanisms to revisit policy as evidence evolves.

The next era of fibromyalgia advocacy can’t be only about discovering treatments. It has to confront what happens after. A therapy that lives in a journal article, an FDA database, or a clinician’s office, but stays financially out of reach, is only half a solution. Medical innovation fulfills its purpose when the right treatment reaches the right patient. That’s the gap we finally have a chance to close.

This commentary reflects the perspective of the Fibromyalgia National Health Organization and is intended for education and advocacy. It is not medical advice and does not constitute an endorsement of any specific product, manufacturer, or treatment. FNHO has no financial relationship with any company named in this article.